Two Sigma Advisers’s CytomX Therapeutics CTMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-335,524
| Closed | -$1.43M | – | 529 |
|
|
2025
Q4 | $1.43M | Buy |
335,524
+295,524
| +739% | +$1.12M | ﹤0.01% | 1318 |
|
|
2025
Q3 | $128K | Buy |
+40,000
| New | +$90.1K | ﹤0.01% | 2204 |
|
|
2024
Q3 | – | Sell |
-158,400
| Closed | -$193K | – | 2329 |
|
|
2024
Q2 | $193K | Buy |
158,400
+11,600
| +8% | +$23.1K | ﹤0.01% | 2225 |
|
|
2024
Q1 | $320K | Buy |
146,800
+105,600
| +256% | +$195K | ﹤0.01% | 2048 |
|
|
2023
Q4 | $63.9K | Sell |
41,200
-66,700
| -62% | -$87.7K | ﹤0.01% | 2377 |
|
|
2023
Q3 | $139K | Sell |
107,900
-121,500
| -53% | -$191K | ﹤0.01% | 2161 |
|
|
2023
Q2 | $395K | Sell |
229,400
-286,700
| -56% | -$476K | ﹤0.01% | 1894 |
|
|
2023
Q1 | $779K | Sell |
516,100
-8,800
| -2% | -$19.9K | ﹤0.01% | 1759 |
|
|
2022
Q4 | $840K | Sell |
524,900
-2,500
| -0.5% | -$3.7K | ﹤0.01% | 1649 |
|
|
2022
Q3 | $765K | Buy |
527,400
+140,400
| +36% | +$216K | ﹤0.01% | 1658 |
|
|
2022
Q2 | $708K | Buy |
387,000
+38,700
| +11% | +$74.1K | ﹤0.01% | 1766 |
|
|
2022
Q1 | $930K | Buy |
348,300
+146,700
| +73% | +$563K | ﹤0.01% | 1676 |
|
|
2021
Q4 | $873K | Buy |
201,600
+400
| +0.2% | +$2.34K | ﹤0.01% | 1630 |
|
|
2021
Q3 | $1.02M | Sell |
201,200
-167,900
| -45% | -$899K | ﹤0.01% | 1610 |
|
|
2021
Q2 | $2.34M | Sell |
369,100
-281,800
| -43% | -$2.19M | 0.01% | 1220 |
|
|
2021
Q1 | $5.03M | Sell |
650,900
-42,000
| -6% | -$332K | 0.01% | 847 |
|
|
2020
Q4 | $4.54M | Buy |
692,900
+138,800
| +25% | +$992K | 0.01% | 866 |
|
|
2020
Q3 | $3.69M | Buy |
554,100
+12,300
| +2% | +$91.2K | 0.01% | 877 |
|
|
2020
Q2 | $4.51M | Buy |
541,800
+54,100
| +11% | +$502K | 0.01% | 840 |
|
|
2020
Q1 | $3.74M | Buy |
487,700
+7,600
| +2% | +$53K | 0.01% | 825 |
|
|
2019
Q4 | $3.99M | Buy |
480,100
+245,200
| +104% | +$1.65M | 0.01% | 937 |
|
|
2019
Q3 | $1.73M | Sell |
234,900
-18,300
| -7% | -$181K | ﹤0.01% | 1172 |
|
|
2019
Q2 | $2.84M | Buy |
253,200
+2,100
| +0.8% | +$22K | 0.01% | 1055 |
|
|
2019
Q1 | $2.7M | Sell |
251,100
-3,000
| -1% | -$44.3K | 0.01% | 1092 |
|
|
2018
Q4 | $3.84M | Sell |
254,100
-10,800
| -4% | -$160K | 0.01% | 901 |
|
|
2018
Q3 | $4.9M | Sell |
264,900
-9,200
| -3% | -$210K | 0.01% | 830 |
|
|
2018
Q2 | $6.27M | Buy |
274,100
+85,300
| +45% | +$2.18M | 0.02% | 760 |
|
|
2018
Q1 | $5.37M | Buy |
188,800
+66,700
| +55% | +$1.9M | 0.01% | 821 |
|
|
2017
Q4 | $2.58M | Buy |
122,100
+69,200
| +131% | +$1.43M | 0.01% | 1129 |
|
|
2017
Q3 | $961K | Buy |
+52,900
| New | +$825K | ﹤0.01% | 1490 |
|
Other funds holding CTMX
KCM
PA
VA
VCM
Two Sigma Advisers's CTMX Position: Q1 2026 in Review
Two Sigma Advisers sold out of CytomX Therapeutics (CTMX) in Q1 2026, closing a stake of 335,524 shares — an estimated $1.43M sold.
Two Sigma Advisers first reported a position in CTMX in Q3 2017 and held it in 30 quarters. The position peaked at $6.27M in Q2 2018. 179 funds tracked by Wall St. Rank hold CTMX as of Q1 2026.
- Two Sigma Advisers reported no remaining CytomX Therapeutics position as of Q1 2026 after selling out during the quarter.
- Two Sigma Advisers sold 335,524 CytomX Therapeutics shares in Q1 2026, an estimated $1.43M.
- Two Sigma Advisers first reported a position in CytomX Therapeutics in Q3 2017 and held it in 30 quarters.
- Two Sigma Advisers's CytomX Therapeutics position peaked at $6.27M in Q2 2018.
- 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2026.
Based on Two Sigma Advisers's 13F filing for Q1 2026.